ClinicalTrials.gov

History of Changes for Study: NCT05301192
Angiotensin-(1-7) Cardiovascular Effects in Aging
Latest version (submitted July 12, 2022) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 March 18, 2022 None (earliest Version on record)
2 April 23, 2022 Study Status and Eligibility
3 June 2, 2022 Study Status
4 July 12, 2022 Study Status
Comparison Format:

Scroll up to access the controls

Study NCT05301192
Submitted Date:  March 18, 2022 (v1)

Open or close this module Study Identification
Unique Protocol ID: STUDY 17401
Brief Title: Angiotensin-(1-7) Cardiovascular Effects in Aging
Official Title: Angiotensin-(1-7) Cardiovascular Effects in Aging
Secondary IDs:
Open or close this module Study Status
Record Verification: March 2022
Overall Status: Not yet recruiting
Study Start: June 1, 2022
Primary Completion: May 31, 2024 [Anticipated]
Study Completion: May 31, 2024 [Anticipated]
First Submitted: March 17, 2022
First Submitted that
Met QC Criteria:
March 18, 2022
First Posted: March 29, 2022 [Actual]
Last Update Submitted that
Met QC Criteria:
March 18, 2022
Last Update Posted: March 29, 2022 [Actual]
Open or close this module Sponsor/Collaborators
Sponsor: Milton S. Hershey Medical Center
Responsible Party: Principal Investigator
Investigator: Amy Arnold
Official Title: Assistant Professor of Neural and Behavioral Sciences
Affiliation: Milton S. Hershey Medical Center
Collaborators:
Open or close this module Oversight
U.S. FDA-regulated Drug: Yes
U.S. FDA-regulated Device: No
Data Monitoring: Yes
Open or close this module Study Description
Brief Summary: Aging is an independent risk factor for developing hypertension and cardiovascular disease; however, the mechanisms underlying age-related cardiovascular disease remain poorly understood. One hallmark of aging is an increase in sympathetic nervous system activity, which can decrease the number and/or sensitivity of β2 adrenergic receptors to reduce dilation of blood vessels and increase blood pressure. Identifying new targets to restore vascular β2 adrenergic receptor signaling may help reduce cardiovascular risk in aging. This study will test the hypothesis that angiotensin-(1-7), a protective hormone of the renin-angiotensin system, can reduce cardiovascular sympathetic outflow and blood pressure and improve endothelial function in older healthy humans.
Detailed Description: A randomized, double blind, placebo-controlled, crossover study will be conducted to determine if acute intravenous angiotensin-(1-7) infusion can reduce cardiovascular sympathetic tone and blood pressure and improve the function of blood vessels in older healthy individuals. This is an outpatient study that requires a screening visit, and if eligible, two study visits separated by at least one week in the Clinical Research Center within the Penn State Milton S. Hershey Medical Center. The study visits will include intravenous infusion of angiotensin-(1-7) or saline for approximately two hours, starting with increasing doses and holding at a steady-state dose. Endothelial function will be measured and blood samples and endothelial cells collected at baseline and at the end of infusions. Blood pressure, heart rate, and muscle sympathetic nerve activity via microneurography will be measured throughout the study. Each study visit will last approximately 4 hours.
Open or close this module Conditions
Conditions: Aging
Keywords: cardiovascular
blood pressure
autonomic nervous system
renin-angiotensin system
endothelial
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Basic Science
Study Phase: Early Phase 1
Interventional Study Model: Crossover Assignment
Number of Arms: 2
Masking: Double (Participant, Investigator)
Allocation: Randomized
Enrollment: 26 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Experimental: Angiotensin-(1-7)
Participants will receive intravenous angiotensin-(1-7) at one study visit for 110 minutes. Angiotensin-(1-7) will be given in escalating doses of 2 ng/kg/min, 4 ng/kg/min, and 8 ng/kg/min. Each of these doses will be infused for 10 minutes. Following the dose escalation, angiotensin-(1-7) will be given at 8 ng/kg/min for an additional 80 minutes. Infusion rates will be calculated for each participant based on body mass.
Drug: Angiotensin-(1-7)
This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
Other Names:
  • Angiotensin I/II (1-7) Acetate
Placebo Comparator: Saline
Participants will receive intravenous saline at one study visit for 110 minutes total. The volume of saline will match the volume of angiotensin-(1-7) infused. Infusion rates will be calculated for each participant based on body mass.
Drug: Saline
Saline will be used as the placebo comparator.
Other Names:
  • Normal saline
  • 0.9% sodium chloride
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Change in Muscle Sympathetic Nerve Burst Rate
[ Time Frame: 110 minutes ]

Muscle sympathetic nerve burst rate will be measured continuously using peroneal nerve microneurography during angiotensin-(1-7) versus saline infusion.
Secondary Outcome Measures:
1. Change in Muscle Sympathetic Nerve Burst Incidence
[ Time Frame: 110 minutes ]

Muscle sympathetic nerve burst incidence will be measured continuously using peroneal nerve microneurography during angiotensin-(1-7) versus saline infusion.
2. Change in Muscle Sympathetic Nerve Amplitude
[ Time Frame: 110 minutes ]

Muscle sympathetic nerve amplitude will be measured continuously using peroneal nerve microneurography during angiotensin-(1-7) versus saline infusion.
3. Change in Muscle Sympathetic Nerve Total Activity
[ Time Frame: 110 minutes ]

Muscle sympathetic nerve total activity will be measured continuously using peroneal nerve microneurography during angiotensin-(1-7) versus saline infusion.
4. Change in Brachial Artery Diameter
[ Time Frame: 110 minutes ]

A blood pressure cuff will be inflated to a suprasystolic pressure for 5 minutes then deflated. Brachial artery diameter will be measured continuously before, during, and after cuff inflation using duplex ultrasound at baseline and at the end of angiotensin-(1-7) versus saline infusion.
5. Change in Systolic and Diastolic Blood Pressure
[ Time Frame: 110 minutes ]

Blood pressure will be measured continuously with a finger and arm cuff during angiotensin-(1-7) versus saline infusion.
6. Change in Heart Rate
[ Time Frame: 110 minutes ]

Heart rate will be measured continuously by electrocardiogram during angiotensin-(1-7) versus saline infusion.
7. Change in Heart Rate Variability
[ Time Frame: 110 minutes ]

Heart rate variability will be calculated from the continuous electrocardiogram recordings obtained during angiotensin-(1-7) versus saline infusion.
8. Change in Plasma Catecholamines
[ Time Frame: 110 minutes ]

Circulating catecholamine levels will be measured in blood samples obtained at baseline and at the end of angiotensin-(1-7) versus saline infusion.
Other Outcome Measures:
1. Change in Angiotensin II
[ Time Frame: 110 minutes ]

Plasma angiotensin II levels will be measured in blood samples obtained at baseline and at the end of angiotensin-(1-7) versus saline infusion.
2. Change in Angiotensin-(1-7)
[ Time Frame: 110 minutes ]

Plasma angiotensin-(1-7) levels will be measured in blood samples obtained at baseline and at the end of angiotensin-(1-7) versus saline infusion.
3. Change in Renin Activity
[ Time Frame: 110 minutes ]

Plasma renin activity will be measured in blood samples obtained at baseline and at the end of angiotensin-(1-7) versus saline infusion.
4. Change in Aldosterone
[ Time Frame: 110 minutes ]

Plasma or serum aldosterone levels will be measured in blood samples obtained at baseline and at the end of angiotensin-(1-7) versus saline infusion.
Open or close this module Eligibility
Minimum Age: 65 Years
Maximum Age: 80 Years
Sex: All
Gender Based:
Accepts Healthy Volunteers: Yes
Criteria:

Inclusion Criteria:

  • Men and women of all races and ethnicities
  • Capable of giving informed consent
  • Fluent in written and spoken English
  • Age 65-80 years
  • Body mass index between 18.5 and 30 kg/m2
  • Normotensive defined as seated blood pressure <130/80 mmHg and without hypertensive medications
  • Satisfactory history and physical exam

Exclusion Criteria:

  • Age ≤ 65 or ≥ 80 years
  • Women who are pregnant, nursing, or taking hormone replacement therapy
  • Decisional impairment
  • Prisoners
  • Alcohol or drug abuse
  • Highly trained athletes
  • Evidence of type I or type II diabetes (fasting glucose > 126 mg/dL or use of anti-diabetic medications)
  • Hypertension or history of serious cardiovascular disease (e.g., myocardial infarction within 6 months, symptomatic coronary artery disease, presence of angina pectoris, significant arrhythmia, congestive heart failure, deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, hypertrophic cardiomyopathy) or cerebrovascular disease (e.g., cerebral hemorrhage, stroke, transient ischemic attack).
  • History or presence of immunological or hematological disorders
  • Impaired hepatic function (aspartate aminotransferase or alanine aminotransferase levels >2 times upper limit of normal range)
  • Impaired renal function (serum creatinine >2.0 mg/dl)
  • Anemia
  • Taking drugs known to influence sympathetic activity (e.g. serotonin-norepinephrine reuptake inhibitors, norepinephrine transporter inhibitors, stimulants).
  • Treatment with anticoagulants (e.g. warfarin)
  • Treatment with chronic systemic glucocorticoid therapy (>7 consecutive days in 1 month)
  • Treatment with any investigational drug in the 1-month preceding the study
  • Known allergy or contraindication to angiotensin converting enzyme inhibitors or angiotensin receptor blockers, both of which increase endogenous angiotensin-(1-7) levels as part of their mechanism of action
  • Inability to give, or withdraw, informed consent
Open or close this module Contacts/Locations
Central Contact Person: Aimee Cauffman, RN
Telephone: 717-531-1617
Email: acauffman@pennstatehealth.psu.edu
Central Contact Backup: Amanda Miller, PhD
Telephone: 717-531-7676
Email: aross1@pennstatehealth.psu.edu
Study Officials: Amy C Arnold, PhD
Principal Investigator
Penn State Medical Center
Locations: United States, Pennsylvania
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States, 17033
Contact:Contact: Amy C Arnold, PhD 717-531-3674 aarnold5@pennstatehealth.psu.edu
Contact:Sub-Investigator: Urs A Leuenberger, MD
Contact:Sub-Investigator: Amanda J Miller, PhD
Contact:Sub-Investigator: Aimee Cauffman, RN
Contact:Sub-Investigator: Cheryl Blaha, RN
Contact:Sub-Investigator: Jian Cui, PhD
Contact:Sub-Investigator: Zhaohui Gao, MD, PhD
Open or close this module IPDSharing
Plan to Share IPD: No
Open or close this module References
Citations:
Links:
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services